Prestige Consumer Healthcare Inc.

$ 46.97 1.80 %

Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.

CEO: Ronald Lombardi - https://www.prestigebrands.com

Price objectif

$66 40.52 %

Recommandation

Buy

DCF

$ 341.90

Loading data...

PBH vs S&P500

Loading data...

No data available.

Quick ratio

2.25

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

12.01

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

3.91

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

10.29 %

reflects reasonable profitability, showing good use of equity.

ROIC

6.65 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

5.01

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.55

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

5.36

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
2.18 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.53 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.29 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.